Country: Canada
Language: English
Source: Health Canada
DICLOFENAC SODIUM; MISOPROSTOL
PFIZER CANADA ULC
M01AB55
DICLOFENAC, COMBINATIONS
50MG; 200MCG
TABLET (DELAYED-RELEASE)
DICLOFENAC SODIUM 50MG; MISOPROSTOL 200MCG
ORAL
250
Prescription
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
Active ingredient group (AIG) number: 0222885001; AHFS:
APPROVED
2001-02-07
_Product Monograph _ _ _ _ARTHROTEC (diclofenac sodium and misoprostol) _ _Page 1 of 46_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR ARTHROTEC ® 50 diclofenac sodium and misoprostol enteric-coated tablets 50 mg diclofenac/200 mcg misoprostol, Oral PR ARTHROTEC ® 75 diclofenac sodium and misoprostol enteric-coated tablets 75 mg diclofenac/200 mcg misoprostol, Oral NSAID with a Mucosal Protective Agent Pfizer Canada ULC 17,300 Trans Canada Highway Kirkland, QC H9J 2M5 Date of Initial Authorization: JAN 15, 1993 Date of Revision: FEB 13, 2024 Submission Control Number: 279263 Wyeth Holdings LLC ® Pfizer Canada ULC, Licensee © Pfizer Canada ULC _ _ _Product Monograph _ _ _ _ARTHROTEC (diclofenac sodium and misoprostol) _ _Page 2 of 46_ RECENT MAJOR LABEL CHANGES 2 CONTRAINDICATIONS 02/2022 3 SERIOUS WARNINGS AND PRECAUTIONS BOX 02/2022 7 WARNINGS AND PRECAUTIONS, Skin 02/2022 7 WARNINGS AND PRECAUTIONS, Skin 02/2024 7 WARNING AND PRECAUTIONS, 7.1.1 pregnant women 02/2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . RECENT MAJOR LABEL CHANGES ............................................................................................ 2 TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ...................................................................... 4 1 INDICATIONS ............................................................................................................... 4 1.1 Pediatrics ................................................................................................................ 4 1.2 Geriatrics ................................................................................................................ 4 2 CONTRAINDICATIONS ................................................................................................. 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ................... Read the complete document